The agreement grants Novo Nordisk an exclusive worldwide licence to utilise Vect-Horus’s platform technology. Credit: JHVEPhoto / Shutterstock.com.

Biotechnology company Vect-Horus has signed a global licence agreement with Novo Nordisk for the development of targeted therapeutics.

The agreement grants Novo Nordisk an exclusive worldwide licence to utilise Vect-Horus’s VECTrans platform technology for delivering cargo aimed at specific targets.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Vect-Horus co-founder and CEO Alexandre Tokay stated: “This agreement is another important step in our strategy to establish commercial partnerships and to secure significant short-term cash to implement our technology and development programmes.

“We look forward to collaborating with Novo Nordisk to unlock the potential of our technology platform and develop more efficient treatments.”

Vect-Horus will be eligible for an upfront payment and has the option to earn up to $327m in additional developmental, regulatory and commercial milestones across three programmes, along with receiving €40m in subsidies and equity.

See Also:

The company will also receive tiered royalties on sales of the products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novo Nordisk Global Research Technologies senior vice-president Brian Vandahl stated: “We are thrilled to work with Vect-Horus by leveraging their platform to discover optimal delivery for specified targets.

“It is an exemplary opportunity for us to utilise external collaboration to further fuel our own innovation processes, with a common goal of improving health outcomes.”

Vect-Horus is focused on the design and development of vectors that enable targeting and delivery of imaging or therapeutic agents to organs, including the brain, and to tumours.